Tranzactioneaza Beyondspring Inc (US.BYSI) - 1.57 USD (%) Tranzactioneaza
Indici
Descriere companie
BeyondSpring Inc. (www.beyondspringpharma.com) is a global biopharmaceutical company that is focused on developing immuno-oncology cancer therapies. The Company’s lead product Plinabulin, which is being studied as an anti-cancer agent in combination with docetaxel in advanced non-small cell lung cancer (NSCLC). The Plinabulin product is a marine-derived small-molecule selective immunomodulating microtubule-binding agent (SIMBA) with a range of immune activities. Its Plinabulin has the immune defense protein, GEF-H1, which leads to two effects: a durable anti-cancer benefits due to the maturation of dendritic cells resulting in activation of tumor antigen-specific T-cells to target cancer cells and early-onset action in chemotherapy-induced neutropenia (CIN) prevention after chemotherapy by boosting the number of hematopoietic stem/progenitor cells (HSPCs).